Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues:
Product, net	$ 154,584	$ 5,421
Revenue from research contracts and other grants			$ 1,253
Total revenues	154,584	5,421	1,253
Cost and expenses:
Cost of sales (excluding amortization of in-licensed rights)	7,353	101
Research and development	166,707	188,272	146,394
Selling, general and administrative	122,682	83,749	75,043
Settlement and license charges	28,427
Amortization of in-licensed rights	1,053	29
Total cost and expenses	326,222	272,151	221,437
Operating loss	(171,638)	(266,730)	(220,184)
Other income (loss) :
Interest (expense) income and other, net	(1,990)	(535)	154
Gain from sale of Priority Review Voucher	125,000
Total other income (loss)	123,010	(535)	154
Loss before income tax expense	(48,628)	(267,265)	(220,030)
Income tax expense	2,060
Net loss	(50,688)	(267,265)	(220,030)
Other comprehensive loss:
Unrealized loss on short-term securities - available-for-sale	(259)	(9)	(16)
Total other comprehensive loss	(259)	(9)	(16)
Comprehensive loss	$ (50,947)	$ (267,274)	$ (220,046)
Net loss per share — basic and diluted	$ (0.86)	$ (5.49)	$ (5.20)
Weighted average number of shares of common stock outstanding for computing basic and diluted net loss per share	58,818	48,697	42,290